Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer

Abstract

Overall our outcomes are consistent with published data and show good survival times can be achieved. The future of advanced NSCLC is in selecting the best treatment approach on a histological and genotypic basis.